Drug Trial Radar · NCT06520540
HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects
Last checked: Nov 19, 2026Latest source record: Jul 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
72
Planned (sponsor's estimate)
Start
Jul 28, 2024
Primary completion
Nov 30, 2024
Study completion Dec 30, 2024
Sponsor
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
• To assess the safety of multiple oral doses of HDM1002 tablets under different titrations in Chinese overweight and obese adult subjects.
Conditions
- Glucagon-Like Peptide-1 Receptor Agonists
Interventions
HDM1002 100 mg QD 12weeksDrug
Participants received maintenance dose of 100 mg HDM1002 administered orally once daily (QD)
HDM1002 200 mg QD 12weeksDrug
Participants received maintenance dose of 200 mg HDM1002 administered orally once daily (QD)
HDM1002 400 mg QD 12weeks,Q 2W for titrationDrug
Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 2W for titration
HDM1002 400 mg QD 12weeks,Q 3W for titrationDrug
Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 3W for titration
PlaceboDevice
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- TEAEs, SAEs, AEs leading to withdrawal, and AEs leading to death, AEs of special interestTime frame: Baseline, Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
HDM1002
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.